| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| Mi | NYRADA INC.: Quotation of Attaching Options | - | ASX | ||
| Mi | NYRADA INC.: Update - Proposed issue of securities - NYR | - | ASX | ||
| Di | NYRADA INC.: Quotation of New Options | 3 | ASX | ||
| Mo | NYRADA INC.: Notice of Initial Substantial Holding - J Moore | 2 | ASX | ||
| Mo | NYRADA INC.: Update - Proposed issue of securities - NYR | 1 | ASX | ||
| 01.11. | NYRADA INC.: Change of Director's Interest Notice - JM | 1 | ASX | ||
| 30.10. | NYRADA INC.: Application for quotation of securities - NYR | 1 | ASX | ||
| 29.10. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 29.10. | NYRADA INC.: PROTECT-MI Phase IIa Clinical Trial Update No 4 | - | ASX | ||
| 27.10. | NYRADA INC.: Securities Purchase Plan Results | - | ASX | ||
| 27.10. | XFRA NEW INSTRUMENTS AVAILABLE ON 27.10.2026 | 295 | Xetra Newsboard | The following instruments on XETRA do have their first trading 27.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.10.2026
Aktien
1 US00774R1041 Aegean Airlines S.A.... ► Artikel lesen | |
| 19.10. | NYRADA INC.: Quarterly Activities Report and Appendix 4C | 2 | ASX | ||
| 15.10. | NYRADA INC.: PROTECT-MI Phase IIa Clinical Trial Update No 3 | - | ASX | ||
| 12.10. | NYRADA INC.: Nyrada Receives Positive FDA Feedback | 2 | ASX | ||
| 12.10. | NYRADA INC.: Attaching Options Prospectus | - | ASX | ||
| 11.10. | NYRADA INC.: Securities Purchase Plan Offer Booklet | - | ASX | ||
| 07.10. | NYRADA INC.: 2026 AGM Letter to Shareholders, Notice of Meeting & Proxy | - | ASX | ||
| 25.09. | NYRADA INC.: Cleansing Statement | 1 | ASX | ||
| 25.09. | NYRADA INC.: Application for quotation of securities - NYR | 1 | ASX | ||
| 21.09. | Nyrada Raises Fresh Capital to Fund Xolatryp Phase IIa And Pipeline Expansion | 2 | smallcaps.com.au |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,205 | -0,14 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| CG ONCOLOGY | 75,93 | 0,00 % | Kurssprung bei CG Oncology: Starke Quartalszahlen und Pipeline-Katalysatoren treiben die Aktie an | ||
| COGENT BIOSCIENCES | 31,645 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| EDGEWISE THERAPEUTICS | 45,030 | -0,02 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| MODERNA | 227,50 | -0,11 % | Halten Zahlen den Crash auf: Apple, Palantir, AMD & Moderna: Wall Street vor explosiver Earnings-Woche! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW45) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,070 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 93,86 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,300 | 0,00 % | Morning Market Movers: Curis, Inc., Darkiris, Amdocs, Nurix Therapeutics See Big Swings | NICOSIA (dpa-AFX) - At 8:05 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,350 | +0,12 % | Stifel cuts Summit Therapeutics stock price target on valuation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,545 | -0,02 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNOVANT | 30,510 | -0,07 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| ADMA BIOLOGICS | 12,720 | 0,00 % | ADMA Biologics hits 10-month high as Asceniv drives Q3 beat | ||
| IMMUNOME | 18,710 | 0,00 % | Immunome-Aktie: Optionsdaten signalisieren Kursschwankung von 9,4 % nach Quartalszahlen | ||
| VERA THERAPEUTICS | 29,790 | +0,02 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| KYMERA THERAPEUTICS | 131,71 | -0,02 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen |